Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Fintepla 2.2 mg/mL oral solution {equilateral_black_triangle}

Active Ingredient:
fenfluramine hydrochloride
Company:  
UCB Pharma Limited See contact details
ATC code: 
N03AX26
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Fintepla Patients and Caregivers alert card

This guide contains information about the risks associated with FINTEPLA and the tests and checks that are needed during treatment with fenfluramine.

{pdf_link}

Fintepla Prescriber Guide

{healthcare_pro_orange} For Healthcare Professionals

This guide is developed to increase awareness and educate prescribers about the risks associated with the use of Fintepla and to inform the prescribing physicians of the need to conduct periodic cardiac monitoring in patients taking Fintepla.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

UCB Pharma Limited
Company image
Address
208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone
+ 44 (0) 1753 534655
Medical Information Direct Line
+44 (0) 1753 777 100
Medical Information e-mail
[email protected]